Cowen & Co. Initiates Coverage On LHC Group with Outperform Rating, Announces Price Target of $209
Cowen & Co. analyst Gary Taylor initiates coverage on LHC Group (NASDAQ:LHCG) with a Outperform rating and announces Price Target of $209.
Return on Capital Employed Overview: LHC Group
After pulling data from Benzinga Pro it seems like during Q2, LHC Group (NASDAQ:LHCG) earned $60.21 million, a 17.75% increase from the preceding quarter. LHC Group also posted a total of $545.91 million in sales, a 4.01% increase since Q1.
Barclays Downgrades LHC Group to Equal-Weight, Lowers Price Target to $207
Barclays analyst Steven Valiquette downgrades LHC Group (NASDAQ:LHCG) from Overweight to Equal-Weight and lowers the price target from $245 to $207.
Credit Suisse Maintains Outperform on LHC Group, Lowers Price Target to $252
Credit Suisse maintains LHC Group (NASDAQ:LHCG) with a Outperform and lowers the price target from $255 to $252.
LHC Group: Q2 Earnings Insights
Shares of LHC Group (NASDAQ:LHCG) moved lower in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 31.71% year over year to $1.62, which beat the estimate of $1.55.
LHC Group Q2 EPS $1.62 Beats $1.55 Estimate, Sales $545.91M Miss $550.42M Estimate
LHC Group (NASDAQ:LHCG) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $1.55 by 4.52 percent. This is a 31.71 percent increase over earnings of $1.23 per share from the same
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
LHC Group and SCP Health Partner To ‘Provide Advanced Clinical Care in the Home’
LHC Group, Inc. (NASDAQ:LHCG) – a national provider of in-home healthcare services and innovations for communities around the nation, and SCP Health – a national clinical leader in acute unscheduled care,